Drug Profile
Research programme: anti-cytokine monoclonal antibodies - XBiotech
Alternative Names: interleukin-1 alpha targeting antibody; X071NAB; X072NAB; X081NAB; X082NAB; X083NABLatest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator XBiotech
- Developer Brigham and Women's Hospital; Massachusetts General Hospital; XBiotech
- Class Monoclonal antibodies
- Mechanism of Action Cytokine inhibitors; Immunomodulators; Interleukin 1 alpha inhibitors; Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis; Chronic obstructive pulmonary disease; Coronary artery restenosis; Crohn's disease; Hypereosinophilic syndrome; Inflammation; Inflammatory bowel diseases; Multiple myeloma; Myocardial reperfusion injury; Psoriasis; Reperfusion injury; Systemic lupus erythematosus; Type 1 diabetes mellitus; Uveitis
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for research development in Crohn's-disease in USA (Parenteral)
- 28 Mar 2020 No recent reports of development identified for research development in Myocardial reperfusion injury in USA (Parenteral)